Rhon-klinikum Ag · XETR:RHK
Rhon-klinikum — 9M 2019 Earnings Presentation
10 slides from Rhon-klinikum's earnings presentation, Nov 8, 2019
Slide 1: Results for the First Nine Months of 2019
Results for the First Nine Months of 2019 8 November 2019 RHÖN-KLINIKUM AG - First Quarter 2017 Results - as of May 5, 2017 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by RHÖN-KLINIKUM AG (the “Company”) and is for information purposes only. This presentation does not constitute, or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any
Slide 3: 9M 2019 results Highlights: Compelling a challenging market environment
9M 2019 results Highlights Compelling a challenging market environment Revenue growth of +4.6% with +0.5% more treated patients in first nine months of 2019 EBITDA margin at 10%; but EBITDA as expected down by -4.9% (yoy) due to various contrary effects* Excessive regulation and bureaucratizat
Slide 4: Extended improvement program
Extended improvement program Further measures to improve our performance Ensuring optimal bed occupancy, length of stay and discharge management Establishment of command and control tools for chief physicians and hospital managers Triage and control of patients flows with additional support by
Slide 5: Key P&L figures First Nine Months of 2019
Key P&L figures First Nine Months of 2019 Performance* vs. Detailed explanation of P&L effects 9M 2019 in € millions 9M 2018 Revenue 970.8 100.0% 4.6% o Besides price-volume-effects and regulatory interventions, revenues are impacted by a stronger case-severity-mix in acute-care areas, CAR T-Cell Ot
Slide 6: Core balance sheet positions as of September 2019
Core balance sheet positions as of 30 September 2019 €1,646m €1,646m RHÖN shows a strong financial solvency, solid balance sheet ratios... 64% €1,053m High Equity ratio of 72% Non-current assets Net Liquidity of €+72m €1,179m 72% Net Debt/EBITDA <0 Equity and a well coordinated multi-stage fin
Slide 7: Outlook: Guidance 2019 & regulatory environment 2020
Outlook Guidance 2019 & regulatory environment 2020 Guidance confirmation GUIDANCE Group REVENUES € 1.30bn +/- 5% fully 2019 confirmed Group EBITDA € 117.5m to € 127.5m Regulatory environment in 2020 DRG price inflator at 3.66% for 2020*; Fixed cost degression discount set to be at -35% (no change
Slide 8: DRG price regulation in 2020 at a glance
Appendix DRG price regulation in 2020 at a glance Average base rate increase in states with RHÖN hospitals Federal Total hospital system budget (weighted by RHÖN case mix) Level Wage sum increase as main reference number for RHÖN effective base rate Benchmark (wage sum) DRG inflation in 2020: +3.6
Slide 9: Shareholder base
Appendix Shareholder base Shareholder structure as of 30 September 2019, according to the most recent notifications of voting rights at that time 25.2% 24.5%* B. Braun 24.5% Free Float 5.2% 75.5% Landeskrankenhilfe Strategic Investors 5.4% 25.1% Ingeborg Münch Asklepios 14.6% Eugen Münch/HCM SE * Sh
Slide 10: IR contact & financial calendar 2020
Appendix IR contact & financial calendar 2020 Financial calendar 2020 21 February 2020 Preliminary results for FY 2019 Conference call 24 March 2020 Publication of annual financial report 2019 IR contact Annual press conference Julian Schmitt Head of Investor Relations & Treasury 7 May 2020 Publicat